![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: EFNA1 |
Gene summary for EFNA1 |
![]() |
Gene information | Species | Human | Gene symbol | EFNA1 | Gene ID | 1942 |
Gene name | ephrin A1 | |
Gene Alias | B61 | |
Cytomap | 1q22 | |
Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | P20827 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
1942 | EFNA1 | GSM4909282 | Human | Breast | IDC | 1.08e-20 | 5.19e-01 | -0.0288 |
1942 | EFNA1 | GSM4909286 | Human | Breast | IDC | 1.27e-02 | -1.78e-01 | 0.1081 |
1942 | EFNA1 | GSM4909296 | Human | Breast | IDC | 4.36e-04 | -1.34e-01 | 0.1524 |
1942 | EFNA1 | GSM4909297 | Human | Breast | IDC | 1.64e-12 | -3.33e-01 | 0.1517 |
1942 | EFNA1 | GSM4909301 | Human | Breast | IDC | 3.69e-42 | 8.12e-01 | 0.1577 |
1942 | EFNA1 | GSM4909304 | Human | Breast | IDC | 2.06e-04 | -3.52e-01 | 0.1636 |
1942 | EFNA1 | GSM4909308 | Human | Breast | IDC | 4.11e-08 | 3.63e-01 | 0.158 |
1942 | EFNA1 | GSM4909311 | Human | Breast | IDC | 2.92e-25 | -2.98e-01 | 0.1534 |
1942 | EFNA1 | GSM4909312 | Human | Breast | IDC | 1.17e-05 | 1.23e-01 | 0.1552 |
1942 | EFNA1 | GSM4909319 | Human | Breast | IDC | 3.65e-28 | -3.00e-01 | 0.1563 |
1942 | EFNA1 | GSM4909321 | Human | Breast | IDC | 3.24e-07 | -6.71e-02 | 0.1559 |
1942 | EFNA1 | brca2 | Human | Breast | Precancer | 1.33e-04 | 3.34e-01 | -0.024 |
1942 | EFNA1 | brca3 | Human | Breast | Precancer | 3.60e-02 | 2.84e-01 | -0.0263 |
1942 | EFNA1 | brca7 | Human | Breast | Precancer | 2.56e-02 | 6.36e-01 | -0.009 |
1942 | EFNA1 | brca10 | Human | Breast | Precancer | 4.25e-12 | 5.64e-01 | -0.0029 |
1942 | EFNA1 | M1 | Human | Breast | IDC | 1.82e-03 | -3.92e-01 | 0.1577 |
1942 | EFNA1 | NCCBC11 | Human | Breast | DCIS | 2.34e-02 | -4.63e-01 | 0.1232 |
1942 | EFNA1 | NCCBC14 | Human | Breast | DCIS | 5.32e-06 | -4.04e-01 | 0.2021 |
1942 | EFNA1 | NCCBC3 | Human | Breast | DCIS | 9.36e-09 | -3.84e-01 | 0.1198 |
1942 | EFNA1 | NCCBC5 | Human | Breast | DCIS | 4.41e-15 | -5.66e-01 | 0.2046 |
Page: 1 2 3 4 5 6 7 8 9 10 11 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:006156410 | Oral cavity | OSCC | axon development | 207/7305 | 467/18723 | 1.01e-02 | 3.51e-02 | 207 |
GO:00504353 | Oral cavity | OSCC | amyloid-beta metabolic process | 36/7305 | 67/18723 | 1.01e-02 | 3.51e-02 | 36 |
GO:00609967 | Oral cavity | OSCC | dendritic spine development | 50/7305 | 99/18723 | 1.31e-02 | 4.34e-02 | 50 |
GO:00342052 | Oral cavity | OSCC | amyloid-beta formation | 31/7305 | 57/18723 | 1.32e-02 | 4.38e-02 | 31 |
GO:00487627 | Oral cavity | OSCC | mesenchymal cell differentiation | 109/7305 | 236/18723 | 1.43e-02 | 4.69e-02 | 109 |
GO:0070242 | Oral cavity | OSCC | thymocyte apoptotic process | 11/7305 | 16/18723 | 1.56e-02 | 4.99e-02 | 11 |
GO:0042176110 | Oral cavity | LP | regulation of protein catabolic process | 177/4623 | 391/18723 | 3.00e-19 | 5.87e-17 | 177 |
GO:0045862110 | Oral cavity | LP | positive regulation of proteolysis | 165/4623 | 372/18723 | 5.40e-17 | 8.46e-15 | 165 |
GO:1903362110 | Oral cavity | LP | regulation of cellular protein catabolic process | 119/4623 | 255/18723 | 1.52e-14 | 1.76e-12 | 119 |
GO:0031647110 | Oral cavity | LP | regulation of protein stability | 132/4623 | 298/18723 | 8.16e-14 | 7.99e-12 | 132 |
GO:1903050110 | Oral cavity | LP | regulation of proteolysis involved in cellular protein catabolic process | 101/4623 | 221/18723 | 7.00e-12 | 5.48e-10 | 101 |
GO:0052547110 | Oral cavity | LP | regulation of peptidase activity | 177/4623 | 461/18723 | 3.01e-11 | 2.00e-09 | 177 |
GO:0050821110 | Oral cavity | LP | protein stabilization | 88/4623 | 191/18723 | 9.15e-11 | 5.51e-09 | 88 |
GO:0052548110 | Oral cavity | LP | regulation of endopeptidase activity | 164/4623 | 432/18723 | 4.33e-10 | 2.20e-08 | 164 |
GO:0034250110 | Oral cavity | LP | positive regulation of cellular amide metabolic process | 76/4623 | 162/18723 | 6.11e-10 | 2.97e-08 | 76 |
GO:0010952110 | Oral cavity | LP | positive regulation of peptidase activity | 88/4623 | 197/18723 | 6.52e-10 | 3.14e-08 | 88 |
GO:0009895110 | Oral cavity | LP | negative regulation of catabolic process | 128/4623 | 320/18723 | 8.36e-10 | 3.91e-08 | 128 |
GO:0031330110 | Oral cavity | LP | negative regulation of cellular catabolic process | 107/4623 | 262/18723 | 5.25e-09 | 2.16e-07 | 107 |
GO:0010950110 | Oral cavity | LP | positive regulation of endopeptidase activity | 79/4623 | 179/18723 | 9.34e-09 | 3.62e-07 | 79 |
GO:0042177110 | Oral cavity | LP | negative regulation of protein catabolic process | 54/4623 | 121/18723 | 1.28e-06 | 3.13e-05 | 54 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0401512 | Cervix | CC | Rap1 signaling pathway | 56/1267 | 210/8465 | 6.23e-06 | 5.61e-05 | 3.32e-05 | 56 |
hsa043609 | Cervix | CC | Axon guidance | 47/1267 | 182/8465 | 8.13e-05 | 5.38e-04 | 3.18e-04 | 47 |
hsa040142 | Cervix | CC | Ras signaling pathway | 51/1267 | 236/8465 | 3.55e-03 | 1.34e-02 | 7.91e-03 | 51 |
hsa040109 | Cervix | CC | MAPK signaling pathway | 62/1267 | 302/8465 | 4.89e-03 | 1.67e-02 | 9.86e-03 | 62 |
hsa0401513 | Cervix | CC | Rap1 signaling pathway | 56/1267 | 210/8465 | 6.23e-06 | 5.61e-05 | 3.32e-05 | 56 |
hsa0436012 | Cervix | CC | Axon guidance | 47/1267 | 182/8465 | 8.13e-05 | 5.38e-04 | 3.18e-04 | 47 |
hsa0401411 | Cervix | CC | Ras signaling pathway | 51/1267 | 236/8465 | 3.55e-03 | 1.34e-02 | 7.91e-03 | 51 |
hsa0401012 | Cervix | CC | MAPK signaling pathway | 62/1267 | 302/8465 | 4.89e-03 | 1.67e-02 | 9.86e-03 | 62 |
hsa04015 | Colorectum | AD | Rap1 signaling pathway | 71/2092 | 210/8465 | 1.72e-03 | 9.68e-03 | 6.18e-03 | 71 |
hsa04360 | Colorectum | AD | Axon guidance | 61/2092 | 182/8465 | 4.36e-03 | 2.17e-02 | 1.38e-02 | 61 |
hsa040151 | Colorectum | AD | Rap1 signaling pathway | 71/2092 | 210/8465 | 1.72e-03 | 9.68e-03 | 6.18e-03 | 71 |
hsa043601 | Colorectum | AD | Axon guidance | 61/2092 | 182/8465 | 4.36e-03 | 2.17e-02 | 1.38e-02 | 61 |
hsa040152 | Colorectum | SER | Rap1 signaling pathway | 54/1580 | 210/8465 | 6.55e-03 | 3.68e-02 | 2.67e-02 | 54 |
hsa040153 | Colorectum | SER | Rap1 signaling pathway | 54/1580 | 210/8465 | 6.55e-03 | 3.68e-02 | 2.67e-02 | 54 |
hsa040154 | Colorectum | MSS | Rap1 signaling pathway | 66/1875 | 210/8465 | 1.03e-03 | 5.94e-03 | 3.64e-03 | 66 |
hsa043602 | Colorectum | MSS | Axon guidance | 54/1875 | 182/8465 | 1.03e-02 | 3.69e-02 | 2.26e-02 | 54 |
hsa040155 | Colorectum | MSS | Rap1 signaling pathway | 66/1875 | 210/8465 | 1.03e-03 | 5.94e-03 | 3.64e-03 | 66 |
hsa043603 | Colorectum | MSS | Axon guidance | 54/1875 | 182/8465 | 1.03e-02 | 3.69e-02 | 2.26e-02 | 54 |
hsa040158 | Colorectum | CRC | Rap1 signaling pathway | 48/1091 | 210/8465 | 4.00e-05 | 8.70e-04 | 5.90e-04 | 48 |
hsa043606 | Colorectum | CRC | Axon guidance | 43/1091 | 182/8465 | 4.38e-05 | 8.70e-04 | 5.90e-04 | 43 |
Page: 1 2 3 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
EFNA1 | EPHA2 | EFNA1_EPHA2 | EPHA | Breast | DCIS |
EFNA1 | EPHA2 | EFNA1_EPHA2 | EPHA | Cervix | ADJ |
EFNA1 | EPHA2 | EFNA1_EPHA2 | EPHA | Cervix | CC |
EFNA1 | EPHA4 | EFNA1_EPHA4 | EPHA | Cervix | CC |
EFNA1 | EPHA4 | EFNA1_EPHA4 | EPHA | CRC | AD |
EFNA1 | EPHA3 | EFNA1_EPHA3 | EPHA | CRC | ADJ |
EFNA1 | EPHA4 | EFNA1_EPHA4 | EPHA | CRC | ADJ |
EFNA1 | EPHA2 | EFNA1_EPHA2 | EPHA | CRC | FAP |
EFNA1 | EPHA3 | EFNA1_EPHA3 | EPHA | CRC | FAP |
EFNA1 | EPHA4 | EFNA1_EPHA4 | EPHA | CRC | FAP |
EFNA1 | EPHA4 | EFNA1_EPHA4 | EPHA | CRC | Healthy |
EFNA1 | EPHA2 | EFNA1_EPHA2 | EPHA | CRC | MSI-H |
EFNA1 | EPHA4 | EFNA1_EPHA4 | EPHA | CRC | MSI-H |
EFNA1 | EPHA5 | EFNA1_EPHA5 | EPHA | CRC | MSI-H |
EFNA1 | EPHA2 | EFNA1_EPHA2 | EPHA | CRC | MSS |
EFNA1 | EPHA2 | EFNA1_EPHA2 | EPHA | Endometrium | ADJ |
EFNA1 | EPHA3 | EFNA1_EPHA3 | EPHA | Endometrium | ADJ |
EFNA1 | EPHA4 | EFNA1_EPHA4 | EPHA | Endometrium | ADJ |
EFNA1 | EPHA2 | EFNA1_EPHA2 | EPHA | Endometrium | AEH |
EFNA1 | EPHA3 | EFNA1_EPHA3 | EPHA | Endometrium | AEH |
Page: 1 2 3 4 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
EFNA1 | SNV | Missense_Mutation | novel | c.154N>G | p.Pro52Ala | p.P52A | P20827 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AC-A5XS-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD |
EFNA1 | SNV | Missense_Mutation | rs755272713 | c.115N>G | p.Ile39Val | p.I39V | P20827 | protein_coding | tolerated(1) | benign(0) | TCGA-B6-A409-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | PD |
EFNA1 | SNV | Missense_Mutation | rs760965678 | c.416N>T | p.Arg139Leu | p.R139L | P20827 | protein_coding | tolerated(0.2) | benign(0.04) | TCGA-AA-A02K-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | folinic | PD |
EFNA1 | SNV | Missense_Mutation | c.500C>T | p.Ala167Val | p.A167V | P20827 | protein_coding | tolerated(0.12) | benign(0.015) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
EFNA1 | SNV | Missense_Mutation | rs548758015 | c.328N>T | p.Arg110Cys | p.R110C | P20827 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-G4-6320-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | oxaliplatin | SD |
EFNA1 | SNV | Missense_Mutation | novel | c.496C>A | p.Leu166Ile | p.L166I | P20827 | protein_coding | tolerated(0.3) | benign(0.017) | TCGA-AJ-A23O-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
EFNA1 | SNV | Missense_Mutation | c.415N>T | p.Arg139Cys | p.R139C | P20827 | protein_coding | deleterious(0.04) | possibly_damaging(0.6) | TCGA-AX-A05S-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unspecific | Carboplatin & Paclitaxel | PD | |
EFNA1 | SNV | Missense_Mutation | novel | c.200N>G | p.Tyr67Cys | p.Y67C | P20827 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AX-A05Z-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
EFNA1 | SNV | Missense_Mutation | rs762981577 | c.184N>A | p.Ala62Thr | p.A62T | P20827 | protein_coding | tolerated(0.61) | benign(0) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
EFNA1 | SNV | Missense_Mutation | novel | c.551N>T | p.Ala184Val | p.A184V | P20827 | protein_coding | deleterious(0.03) | possibly_damaging(0.79) | TCGA-BG-A222-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |